Sai Parenteral’s IPO
Sai Parenteral's IPO is a Mainboard book-built issue comprising a fresh issue of equity shares aggregating up to ₹285 crore and an Offer for Sale (OFS) of up to 31,57,880 equity shares. The company aims to list its equity shares on the NSE and BSE.
Sai Parenteral’s IPO Details
Sai Parenteral's IPO bidding started from Mar 24, 2026 and ended on Mar 27, 2026. The allotment for Sai Parenteral's IPO was finalized on Mar 30, 2026. The shares got listed on the NSE and the BSE on Apr 2, 2026.
Sai Parenteral’s IPO Timeline (Tentative)
The Sai Parenteral's IPO timeline includes all the important events of the public issue, such as the IPO opening and closing dates, basis of allotment, refund initiation, credit of shares to Demat accounts, and the expected listing date. Investors should keep track of these dates to ensure timely participation and monitor the allotment process.
| Event | Tentative Date |
|---|---|
| IPO Open Date | Tue, Mar 24, 2026 |
| IPO Close Date | Fri, Mar 27, 2026 |
| Basis of Allotment | Mon, Mar 30, 2026 |
| Initiation of Refunds | Wed, Apr 1, 2026 |
| Credit of Shares to Demat | Wed, Apr 1, 2026 |
| Listing Date | Thu, Apr 2, 2026 |
| IPO Opens | Mar 24, 2026 |
| IPO Closes | Mar 27, 2026 |
| Basis of Allotment | Mar 30, 2026 |
| Refund | Apr 1, 2026 |
| Credit of Shares | Apr 1, 2026 |
| Listing | Apr 2, 2026 |
Sai Parenteral’s IPO Lot Size
Investors can bid for a minimum of 38 shares and in multiples thereof.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 38 | 14,896 |
| Retail (Max) | 13 | 494 | 1,93,648 |
| S-HNI (Min) | 14 | 532 | 2,08,544 |
| S-HNI (Max) | 67 | 2,546 | 9,98,032 |
| B-HNI (Min) | 68 | 2,584 | 10,12,928 |
Sai Parenteral’s IPO Reservation
Sai Parenteral's IPO comprises a total issue size of 1,04,28,288 shares. Out of which, 52,14,143 (50.00%) are allocated to QIB, 15,64,244 (15.00%) allocated to NII 36,49,901 (35.00%) allocated to RII.
About Sai Parenteral’s
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Competitive Strength:
- Diversified generic formulations player with an established track record.
- Strategically located and accredited Manufacturing Facilities.
- Strong focus on CDMO business.
- Well-established distribution network in India and overseas.
- Track record of value-accretive acquisitions.
- Experienced Promoters and Senior Management with extensive domain knowledge.
Strengths
- Diversified generic formulations business with an established operating track record since 2001 and significant business expansion under the current management since 2016.
- Broad product portfolio spanning multiple dosage forms, including injectables, tablets, capsules, liquid orals, and ointments, catering to diverse therapeutic segments.
- Strong manufacturing infrastructure with multiple manufacturing facilities and internationally accredited units supporting both domestic and export markets.
- Growing domestic and international presence, serving government agencies, hospitals, pharmaceutical companies, distributors, and export customers.
- Expansion into regulated international markets through the acquisition of Noumed Pharmaceuticals Pty Limited, strengthening the company's global footprint.
- Experienced promoters and management team with expertise in pharmaceutical manufacturing, operations, and business development.
- Focus on quality, regulatory compliance, and operational efficiency, supported by certifications and approvals from various regulatory authorities.
- Consistent emphasis on product diversification and capacity expansion, positioning the company for future growth opportunities.
Risks to Consider
- The company operates in a highly regulated pharmaceutical industry, and failure to comply with regulatory requirements or maintain approvals may adversely affect its business.
- Manufacturing operations depend on regulatory inspections, certifications, and product approvals, and any adverse observations could impact production and sales.
- A significant portion of revenue is generated from pharmaceutical formulations, making the business sensitive to changes in demand, pricing, and competition.
- The company depends on the uninterrupted supply of raw materials and active pharmaceutical ingredients (APIs), and supply chain disruptions could affect operations.
- The pharmaceutical industry is highly competitive, with competition from domestic and international manufacturers that may impact market share and profitability.
- International business is subject to foreign exchange fluctuations, regulatory changes, and country-specific risks, which could affect export revenue.
- Future growth depends on successful integration of acquisitions, capacity expansion, and execution of business strategies, and any delays or challenges could impact financial performance.
- The company may face product liability claims, product recalls, or litigation, which could adversely affect its reputation, operations, and financial condition.
KPIs & Valuation
The Key Performance Indicators (KPIs) and valuation metrics help investors understand Sai Parenteral's Limited's earnings, return ratios, and net asset value. Certain valuation metrics, including the P/E ratio and market capitalization, will be finalized after the company announces the IPO price band.
Objects of the Issue
Powerica Limited intends to utilize the net proceeds from the fresh issue to strengthen its financial position and support future business growth. The company has outlined the proposed utilization of funds in the Red Herring Prospectus.
- Prepayment or repayment of certain outstanding borrowings availed by the company, in part or full.
- General corporate purposes.
- Meeting issue-related expenses in accordance with applicable regulations.
Promoters, Lead Managers & Registrar
Powerica Limited is promoted by experienced promoters with decades of expertise in the power generation and renewable energy sectors. The IPO is being managed by reputed Book Running Lead Managers (BRLMs), while the registrar will oversee the IPO application process, allotment, refunds, and credit of shares to investors' Demat accounts.
Promoters
Lead Managers (BRLM)
Sai Parenteral’s IPO Review
How to Apply
Applying for the Sai Parenteral's IPO is simple through the ASBA (Application Supported by Blocked Amount) facility or the UPI mechanism. Investors can submit their IPO applications using their preferred stockbroker or an ASBA-enabled bank during the subscription period.
Steps to Apply Online
- Log in to your stockbroker's website or mobile trading app.
- Go to the IPO or Current IPOs section.
- Select Sai Parenteral's IPO from the list of available IPOs.
- Enter the number of lots you wish to apply for.
- Choose your bid price or select the Cut-off Price (available only for Retail Individual Investors).
- Enter your UPI ID if applying through a broker, or use your bank's ASBA facility.
- Review the application details and submit your IPO application.
- Approve the UPI mandate request before the specified deadline.
- The application amount will be blocked in your bank account until the allotment process is completed.
- If shares are allotted, they will be credited to your Demat account. If not, the blocked amount will be released by your bank.
Last updated Aug 7, 2026.